Generic Name and Formulations:
Ticarcillin (as disodium) 3g, clavulanate (as potassium) 0.1g; IV inj; sodium content 4.75mEq/g of ticarcillin; potassium content 0.15mEq/g of Timentin.
Indications for TIMENTIN:
Susceptible bacterial septicemia (adults only), lower respiratory, bone and joint, skin and skin structure, urinary tract, gynecologic and intraabdominal infections.
By IV infusion over 30 minutes. >60kg: Systemic and UTI: 3.1g every 4–6 hours. Gynecologic: moderate: 200mg/kg/day of ticarcillin in divided doses every 6 hours; severe: 300mg/kg/day in divided doses every 4 hours. <60kg: 200–300mg/kg/day in divided doses every 4–6 hours. Renal impairment: reduce dose; see literature.
<3months: not recommended. Give by IV infusion over 30 minutes. ≥3months: (<60kg): mild-to-moderate infections: 200mg/kg per day of ticarcillin in equal divided doses every 6 hrs: severe infections: 300mg/kg per day of ticarcillin in equal divided doses every 4 hours. ≥3months (≥60kg): mild-to-moderate infections: 3.1g every 6 hrs; severe infections: 3.1g every 4 hours. Renal impairment: reduce dose; see literature.
Cephalosporin, imipenem or other allergy. Not for use in children for septicemia or H. influenzae type b infections. Heart disease. Sodium restricted diets. Monitor serum electrolytes (esp. potassium) and renal, hepatic, hematopoietic function during prolonged therapy. Discontinue if bleeding problems occur and treat. Pregnancy (Cat.B). Nursing mothers.
Probenecid increases ticarcillin levels. May cause false (+) Coomb's test.
Antipseudomonal penicillin + β-lactamase inhibitor.
Inj site reactions, rash, pruritus, drug fever, GI upset, blood dyscrasias, hemorrhage, hypokalemia, superinfection, anaphylaxis, CNS stimulation, elevated liver enzymes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy